Proton-pump inhibitor litigation · Evidence guide
The PPI cases turn kidney-risk signals into contested causation claims
Plaintiffs allege proton-pump inhibitors caused kidney injuries. FDA labeling recognizes acute tubulointerstitial nephritis, while broader chronic-kidney evidence remains largely observational.
What the lawsuits allege
The federal cases allege that proton-pump inhibitors caused kidney injuries and that warnings were inadequate. Defendants took different positions on centralization. The JPML transfer order organized pretrial work; it did not decide whether a medicine caused an individual's condition.
What the label and research establish
FDA-approved pantoprazole labeling says acute tubulointerstitial nephritis has been observed in people taking PPIs. That warning identifies a recognized adverse event; it does not establish that PPIs cause every form of chronic kidney disease alleged in the litigation.
A systematic review and meta-analysis reported associations between PPI use and several kidney outcomes, but rated the underlying evidence low or insufficient. Observational associations can be affected by differences between people who do and do not receive these medicines, so they cannot decide individual causation on their own.
Where the cases stand
MDL 2789 is in the District of New Jersey before Judge Claire C. Cecchi. JPML listed 11,321 actions pending on August 3, 2026. That is a docket count, not a tally of proven injuries.
Verification ledger
Primary sources
PPI Products Liability transfer order
The allegation and centralization record.
MDL 2789, Document 113
Protonix prescribing information
A current FDA-approved PPI kidney warning.
Section 5.4
PPI use and adverse kidney outcomes
A meta-analysis with explicit evidence-quality limits.
PMID 28339835
Pending MDLs
The dated federal docket snapshot.
Page 1, MDL 2789